AI tool to predict brain tumor risk in lung cancer
Part of Brain & nervous system, Cancer, Lungs & breathing clinical trials.
This study uses an artificial intelligence (AI) tool to look at your scans and health information to better predict whether lung cancer might spread to the brain and how the disease may progress. It aims to help doctors make more personalized treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with lung cancer (confirmed by a biopsy or similar test).
- You are able to take care of yourself (score of 70 or higher on the Karnofsky Performance Scale).
- You are receiving standard treatment for your lung cancer, such as surgery, radiation, chemotherapy, or other standard medications.
- You have had a contrast-enhanced MRI of the brain and a contrast-enhanced CT of the chest before starting treatment.
- You are willing to provide consent to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses artificial intelligence to predict if early-stage lung cancer has spread to nearby lymph nodes. It aims to help doctors make better treatment decisions for patients with stage 1 lung cancer.
This study tests an artificial intelligence (AI) system that uses your health information and medical images to better judge cancer risk and support diagnosis and treatment decisions. It may help doctors make more consistent assessments by combining clinical records, imaging, and other lab-style data.
This trial tests whether artificial intelligence can help doctors plan better treatment for non-small cell lung cancer (NSCLC). A team of specialists will use AI tools alongside their usual approach to see if it improves care and safety.
This trial is testing whether artificial intelligence can help predict how well people with advanced non-small cell lung cancer (NSCLC) respond to immunotherapy or chemo-immunotherapy. If you have stage IV NSCLC and have started this treatment, your data may help build a better prediction tool.
This trial tests an artificial intelligence platform that helps doctors predict if lymph nodes in the chest contain cancer during a routine ultrasound procedure. It aims to make staging more accurate for people with suspected or confirmed non-small cell lung cancer.
This trial uses brain MRI scans and deep learning to predict whether non-small cell lung cancer that has spread to the brain has certain gene changes (EGFR or ALK). Knowing this may help guide treatment without needing additional tissue testing.
Hear when a new AI (Artificial Intelligence) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.